Clinical Trials · NCT05444153
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
- Phase
- Phase 3
- Recruitment status
- Withdrawn
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 0
- Start date
- Oct 2022
- Locations
- See registry
- Primary endpoint
- Participants acheiving glycated haemoglobin (HbA1c) less than (<) 7 percentage (%) (Yes/No)